Nasus Pharma (NSRX) sets vote on share capital, equity pay

Rhea-AI Filing Summary

Nasus Pharma Ltd. has called a Special General Meeting of shareholders for March 5, 2026, in Tel Aviv. Shareholders of record on February 9, 2026 will be entitled to vote.

On the agenda are proposals to increase authorized share capital, amend the articles of association, approve equity-based compensation for non-executive directors and the Chief Financial Officer, approve a milestone-based grant for the Chief Executive Officer, and approve a U.S. sub-plan to the company’s 2019 Incentive Option Plan.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of January 2026 (Report No. 2)

Commission File Number: 001-42796

NASUS PHARMA Ltd.

(Translation of registrant’s name into English)

Yigal Alon 65

Tel Aviv, Israel 6744317

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein are the Notice of Meeting, Proxy Statement and Proxy Card for the Special General Meeting of Shareholders of Nasus Pharma Ltd. (the “Company”) to be held on Thursday, March 5, 2026 (the “Meeting”).

Only shareholders of record who hold ordinary shares, no par value, of the Company at the close of business on Monday, February 9, 2026 will be entitled to notice of and to vote at the Meeting and any postponements or adjournments thereof.

Copies of the Notice of Special General Meeting, Proxy Statement and Form of Proxy Card for the Meeting are furnished herewith as Exhibits 99.1, 99.2 and 99.3, respectively.

2

Exhibits No.
99.1		Notice for the Special General Meeting of Shareholders to be held on March 5, 2026.
99.2		Proxy Statement for the Special General Meeting of Shareholders to be held on March 5, 2026.
99.3		Form of Proxy Card for the Special General Meeting of Shareholders to be held on March 5, 2026.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Nasus Pharma Ltd.
Date: January 29, 2026	By:	/s/ Dan Teleman
	Name:	Dan Teleman
	Title:	Chief Executive Officer

4

Exhibit 99.1

Dear Nasus Pharma Ltd. Shareholders:

We cordially invite you to attend the Special General Meeting of Shareholders of Nasus Pharma Ltd. (the “Company”), to be held on March 5, 2026 at 2:00 p.m. Israel time, at the Company’s legal counsel’s office, located at 28 Ha’Arbaa St., Hagag Towers, North Tower, 34^th Floor, Tel Aviv, 6744317 Israel (the “Meeting”).

At the Meeting, shareholders will be asked to consider and vote on the matters listed in the enclosed Notice of Special General Meeting of Shareholders (the “Notice”).

Our board of directors recommends that you vote FOR each of the Proposals listed in the Notice.

Only shareholders of record at the close of business on February 9, 2026, (the “Record Date”), are entitled to notice of and to vote at the Meeting, either in person or by appointing a proxy to vote in their stead at the Meeting as detailed in the Notice.

We look forward to greeting as many of you as can attend the Meeting.

Sincerely,

/s/ Dan Teleman

Dan Teleman

Chief Executive Officer

January 29, 2026

Nasus Pharma Ltd.

Notice of SPECIAL General Meeting of shareholders

Notice is hereby given that a Special General Meeting of Shareholders (the “Meeting”) of Nasus Pharma Ltd. (the “Company”) will be held on March 5, 2026, at 2:00 p.m. Israel time, or at any adjournment or postponement thereof, at the Company’s legal counsel’s office, located at 28 Ha’Arbaa St., Hagag Towers, North Tower, 34^th Floor, Tel Aviv, Israel.

The following matters are on the agenda for the Meeting:

	1.	consider a proposal to increase the Company’s authorized share capital, and to amend the Company’s amended and restated articles of association to reflect the same; and
	2.	consider a proposal to approve a grant of equity-based compensation to non-executive directors of the Company; and
	3.	consider a proposal to approve a grant of equity-based compensation to Mr. Eyal Rubin, the Company’s Chief Financial Officer; and
	4.	consider a proposal to approve a milestone-based grant for the Company’s Chief Executive Officer, Mr. Dan Teleman; and
	5.	consider a proposal to approve the Sub-Plan for U.S. Persons to the Company’s 2019 Incentive Option Plan.

Board Recommendation

Our board of directors (the “Board of Directors”) unanimously recommends that you vote “FOR” the above proposed resolutions, which are described in the attached proxy statement (the “Proxy Statement”).

Record Date

Shareholders of record at the close of business on February 9, 2026 (the “Record Date”), are entitled to notice of and to vote at the Meeting, either in person or by appointing a proxy to vote in their stead at the Meeting (as detailed below).

Required Vote and Voting Procedures

Pursuant to the Israeli Companies Law 5759-1999 (the “Companies Law”), each of Proposals 1 and 5, requires a Simple Majority (as defined in the Proxy Statement).

Each of Proposals 2, 3 and 4 described hereinafter, requires a Special Majority (as defined in the Proxy Statement).

How You Can Vote

A form of proxy card for use at the Meeting is attached to the Proxy Statement and a voting instruction form, together with a return envelope, will be sent to holders of the Company’s ordinary shares, no par value per share (“Ordinary Shares”). By appointing “proxies,” shareholders may vote at the Meeting whether or not they attend. If a properly executed proxy card in the attached form is received by the Company at least four (4) hours prior to the Meeting, including a certificate of ownership and a copy of your identity card, passport or certification of incorporation as the case may be, all of the Ordinary Shares represented by the proxy card shall be voted as indicated on the form.

Subject to applicable law and the rules of the NYSE American LLC, in the absence of instructions, the Ordinary Shares represented by properly executed and received proxy cards will be voted “FOR” the proposed resolutions to be presented at the Meeting for which the Board of Directors recommends a vote “FOR”.

Shareholders of record

If your shares are registered directly in your name with our transfer agent, VStock Transfer LLC, you are considered, with respect to those shares, the shareholder of record. In such case, these proxy materials are being sent directly to you. As the shareholder of record, you have the right to use the proxy card included with the Proxy Statement to grant your voting proxy directly to each of Mr. Eyal Rubin, Chief Financial Officer (e-mail address eyalr@nasuspharma.com) at least four (4) hours prior to the Meeting, or to vote in person at the Meeting. Proxy cards received after the aforementioned time will not be tabulated.

Beneficial Owners

If your shares are held through a bank, broker or other nominee, they are considered to be held in “street name” and you are the beneficial owner with respect to those shares. A beneficial owner as of the Record Date has the right to direct the bank, broker or nominee how to vote shares held by such beneficial owner at the Meeting. If your shares are held in “street name” as of the Record Date, these proxy materials are to be forwarded to you by your bank, broker or nominee who is considered, with respect to those shares, as the shareholder of record, together with a voting instruction card for you to use in directing the bank, broker or nominee how to vote your shares.

You also may attend the Meeting. In such case, because a beneficial owner is not a shareholder of record, you may not vote those shares directly at the Meeting unless you obtain a “legal proxy” from the bank, broker or other nominee that holds your shares directly, giving you the right to vote the shares at the Meeting.

Absent specific instructions from the beneficial owner of the shares, brokers are not allowed to exercise their voting discretion, among other things, with respect to all of the Proposals listed above, which we believe are considered “non-routine” under applicable rules, and therefore, a “broker non-vote” occurs with respect to such uninstructed shares. Therefore, it is important for a shareholder that holds Ordinary Shares through a bank or broker to instruct its bank or broker how to vote its shares if the shareholder wants its shares to count for all of the Proposals.

Voting Results

The final voting results will be tallied by the Company, in consultation with its legal counsel, based on the information provided by VStock Transfer LLC or otherwise, and the overall results of the Meeting will be published following the Meeting in a Report of Foreign Private Issuer on Form 6-K that will be furnished to the U.S. Securities and Exchange Commission (the “SEC”).

Sincerely,

/s/ Dan Teleman

Dan Teleman

Chief Executive Officer

January 29, 2026

FAQ

What is Nasus Pharma (NSRX) asking shareholders to vote on at the March 5, 2026 meeting?

Nasus Pharma will ask shareholders to approve an increase in authorized share capital, amendments to its articles, equity-based compensation for non-executive directors and the CFO, a milestone-based grant for the CEO, and a U.S. sub-plan to the 2019 Incentive Option Plan.

Who can vote at Nasus Pharma (NSRX) March 5, 2026 special shareholder meeting?

Shareholders of record at the close of business on February 9, 2026 can vote. This record date determines who is entitled to receive notice of the meeting and vote either in person or by proxy on the proposals listed in the proxy statement.

How can Nasus Pharma (NSRX) shareholders submit votes for the special meeting?

Shareholders of record may vote by returning a properly executed proxy card at least four hours before the meeting or by attending in person. Beneficial owners holding shares in “street name” must give voting instructions to their bank or broker or obtain a legal proxy to vote directly.

Where will Nasus Pharma (NSRX) hold its March 5, 2026 special shareholder meeting?

The special meeting will be held at 2:00 p.m. Israel time on March 5, 2026 at the company’s legal counsel’s office, 28 Ha’Arbaa Street, Hagag Towers, North Tower, 34th Floor, Tel Aviv, Israel, as stated in the meeting notice to shareholders.

What voting thresholds apply to the proposals at Nasus Pharma (NSRX) special meeting?

Under Israeli Companies Law, Proposals 1 and 5 require a Simple Majority as defined in the proxy statement. Proposals 2, 3 and 4, relating mainly to compensation matters, require a Special Majority, also defined in the accompanying proxy materials sent to shareholders.

What happens if Nasus Pharma (NSRX) shareholders do not give voting instructions on the proposals?

If a shareholder of record sends a signed proxy card without instructions, shares will be voted FOR proposals backed by the board. For beneficial owners, uninstructed shares held by brokers generally result in broker non-votes on these non-routine proposals, meaning those shares are not counted.